Compare Dollar Tree, Inc. (DLTR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs BIO-TECHNE Corp — how do they compare? Dollar Tree, Inc. trades at $127.7 (market cap $24.86B), while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: Dollar Tree, Inc. is far larger — about 2.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals.
| DLTR | TECH | |
|---|---|---|
Market Cap | $24.86B | $11.24B |
Sector | Health | Health |
52-Week High | $141.21 | $72.29 |
52-Week Low | $85.04 | $43.31 |
Enterprise Value | $31.45B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $130.9, up 0.94% on the day, with a bullish technical outlook and strong profitability metrics including a 34.71% ROE. Recent quarters have consistently beaten EPS estimates, and the company announced a $2.5 billion share repurchase authorization in July 2026. Revenue for 2025 was $17.58 billion, though net income was negative due to a significant tax charge, with a rebound to profitability projected for 2026.
The stock presents a mixed outlook: analyst consensus is a 'Buy' with a $129.08 price target near the current price, supported by solid cash flow and margin improvements. Key risks include competitive pressures, tariff impacts on margins, and execution of the turnaround strategy amid consumer spending shifts.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
